Loading...
XKRX
234080
Market cap131mUSD
May 20, Last price  
11,810.00KRW
1D
2.43%
1Q
13.67%
Jan 2017
-13.64%
IPO
-31.14%
Name

JW Life Science Corp

Chart & Performance

D1W1MN
XKRX:234080 chart
P/E
4.16
P/S
0.82
EPS
2,840.73
Div Yield, %
—
Shrs. gr., 5y
-0.46%
Rev. gr., 5y
5.50%
Revenues
222.48b
+7.55%
84,121,031,19089,090,518,89088,614,186,790111,121,369,220125,950,120,610132,290,404,970143,599,849,110155,230,052,160170,220,779,250183,521,045,080169,816,950,010188,931,165,240206,860,371,797222,478,095,660
Net income
43.99b
+56.29%
2,658,535,4003,467,947,0101,632,618,9309,356,571,44012,864,212,71015,161,608,51016,782,714,41015,820,963,90021,938,439,04017,300,052,45012,913,619,14014,961,266,84028,143,966,40043,987,530,990
CFO
50.69b
+34.91%
14,765,055,03017,554,452,04010,795,451,51013,844,732,67025,896,778,71016,081,152,66022,050,000,57036,129,922,79024,275,563,95046,754,700,49030,165,045,65014,128,750,70037,574,248,44050,689,792,230
Dividend
Dec 27, 2023500 KRW/sh

Profile

JW Lifescience Corporation engages in the development, production, and sale of infusion solutions in South Korea and internationally. It offers basic intravenous fluid that comprises water, electrolytes, and glucose; nutrient infusion solution that consist of nutrients, such as amino acids, lipids, proteins, vitamins, and minerals; and special infusion solutions. The company was formerly known as JW Co. Ltd. and changed its name to JW Lifescience Corporation in April 2011. JW Lifescience Corporation was founded in 1994 and is based in Dangjin, South Korea.
URL
https://www.jw-lifescience.co.kr/
IPO date
Oct 27, 2016
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
222,478,096
7.55%
206,860,372
9.49%
188,931,165
11.26%
Cost of revenue
179,741,590
169,330,980
155,308,943
Unusual Expense (Income)
NOPBT
42,736,506
37,529,392
33,622,222
NOPBT Margin
19.21%
18.14%
17.80%
Operating Taxes
15,038,973
5,564,302
5,820,578
Tax Rate
35.19%
14.83%
17.31%
NOPAT
27,697,533
31,965,089
27,801,644
Net income
43,987,531
56.29%
28,143,966
88.11%
14,961,267
15.86%
Dividends
(7,742,277)
(7,742,277)
(7,742,277)
Dividend yield
4.60%
3.89%
4.12%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
36,162,660
46,098,144
37,147,858
Long-term debt
34,601,568
306,275
30,218,595
Deferred revenue
Other long-term liabilities
4,218,544
141,950
508,067
Net debt
61,195,528
4,393,726
58,818,974
Cash flow
Cash from operating activities
50,689,792
37,574,248
14,128,751
CAPEX
(10,306,665)
(8,153,142)
(8,293,469)
Cash from investing activities
(68,033,945)
8,036,512
(28,247,198)
Cash from financing activities
1,776,470
(29,308,312)
13,115,140
FCF
(6,909,847)
38,119,074
20,447,462
Balance
Cash
9,621,540
28,347,661
28,872,694
Long term investments
(52,840)
13,663,033
(20,325,215)
Excess cash
31,667,675
Stockholders' equity
172,008,416
137,806,616
134,531,104
Invested Capital
273,900,824
174,180,223
203,085,383
ROIC
12.36%
16.95%
14.97%
ROCE
15.19%
18.07%
16.39%
EV
Common stock shares outstanding
15,473
15,485
15,485
Price
10,880.00
-15.46%
12,870.00
5.93%
12,150.00
-12.27%
Market cap
168,351,267
-15.52%
199,286,210
5.93%
188,137,331
-12.81%
EV
229,546,795
203,679,936
246,956,305
EBITDA
58,473,650
53,060,095
48,578,313
EV/EBITDA
3.93
3.84
5.08
Interest
2,060,596
2,693,103
3,091,935
Interest/NOPBT
4.82%
7.18%
9.20%